6533b828fe1ef96bd1288528

RESEARCH PRODUCT

Needle track seeding following percutaneous procedures for hepatocellular carcinoma.

Giuseppe CabibboAntonio CraxìGiuseppe Cabibbo

subject

medicine.medical_specialtyPercutaneousHepatologymedicine.diagnostic_testbusiness.industryRadiofrequency ablationmedicine.medical_treatmentReviewLiver transplantationmedicine.diseaselaw.inventionSurgerysurgical procedures operativelawLiver biopsyHepatocellular carcinomaBiopsymedicineSeedingPercutaneous ethanol injectionbusiness

description

Neoplastic seeding may arise after diagnostic or therapeutic percutaneous procedures for hepatocellular carcinoma. The true incidence of seeding with hepatocellular carcinoma is difficult to assess precisely, but a significant risk of seeding exists and is greater when performing diagnostic biopsy as compared to therapeutic percutaneous procedures [radiofrequency ablation, radiofrequency ablation (RFA); percutaneous ethanol injection, Percutaneous ethanol injection (PEI)]. Whenever liver transplantation is feasible, diagnostic needle biopsies should be avoided, but RFA and PEI are often needed as “bridge” treatments. The role of adjuvant treatments in reducing the incidence of seeding following RFA or PEI requires further evaluation.

10.4254/wjh.v1.i1.62https://pubmed.ncbi.nlm.nih.gov/21160966